Current Report Filing (8-k)
May 12 2022 - 04:09PM
Edgar (US Regulatory)
0000744452 false 0000744452 2022-05-12
2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 12, 2022
Applied DNA Sciences, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
(State or other jurisdiction
of incorporation)
|
001-36745
(Commission File Number)
|
59-2262718
(IRS Employer
Identification No.)
|
50 Health Sciences Drive
Stony Brook,
New York
11790
(Address of principal executive offices; zip code)
Registrant’s telephone number, including area code:
631-240-8800
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $0.001 par value |
|
APDN |
|
The
Nasdaq Stock Market |
Item 2.02 Results of Operations and Financial
Condition.
On May 12, 2022, Applied DNA Sciences, Inc. (“Applied DNA Sciences”
or the “Company”) issued a press release announcing its results of
operations for the three-month period ended March 31, 2022. A copy
of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
The information furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities under that
Section and shall not be deemed to be incorporated by reference
into any filing of the Company under the Securities Act of 1933 or
the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Date: May 12,
2022 |
APPLIED DNA SCIENCES,
INC. |
| |
|
|
| |
By: |
/s/ James A.
Hayward |
| |
Name: |
James A.
Hayward |
| |
Title: |
Chief Executive
Officer |
EXHIBIT INDEX
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Dec 2022 to Jan 2023
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Jan 2022 to Jan 2023
